Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To quantify the price that private payers pay hospitals for head and neck squamous cell carcinoma (HNSCC) treatments and identify hospital-level factors associated with price variation.
Study Design: Cross-sectional study.
Setting: Price transparency files.
Methods: Files from the top 50 hospitals in otolaryngology according to the US News and World Report were analyzed between December 2021 and June 2022. This study analyzed the following Food and Drug Administration-approved HNSCC therapies: pembrolizumab, nivolumab, cetuximab, cisplatin, carboplatin, and paclitaxel.
Results: Twenty-four (48%) hospitals reported prices for at least 1 medication in our sample. Newer biologics were significantly more expensive than traditional chemotherapeutic agents. Given approved medication regimens, all biologics in our sample have similar annual costs. Price markups over acquisition costs ranged between 109% (pembrolizumab, nivolumab) and 530% for carboplatin. Across hospitals, prices varied the most for paclitaxel, the cheapest medication in our sample, and prices varied the least for pembrolizumab the most expensive medication in our sample. Hospital 340B status and geographic location in the northeast/west are associated with lower price markups.
Conclusion: Price nondisclosure remains a significant problem among hospitals. Newer biological medications are more expensive when compared to traditional chemotherapeutic agents. Prices vary significantly across hospitals, with lower price markups observed in 340B hospitals as well as hospitals located in the geographic northeast and west. It remains to be seen if price transparency will lead to more uniform pricing or lower costs of treatments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ohn.308 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Testing the Efficacy of a Web-Based Intervention for Loss and Bereavement in Later Life (AgE-health Study): Results From a Randomized Controlled Trial.
J Med Internet Res
September 2025
Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Leipzig, Germany.
Background: The loss of a loved one is a common yet stressful event in later life. Internet- and mobile-based interventions have been proposed as an effective treatment approach for individuals with prolonged grief.
Objective: The AgE-health study aimed to investigate the efficacy of an eHealth intervention, trauer@ktiv, in reducing prolonged grief symptoms in a sample of older adults.
Synovial MS4A4A correlates with inflammation and counteracts response to corticosteroids in arthritis.
Proc Natl Acad Sci U S A
September 2025
Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute and Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, United Kingdom.
MS4A4A belongs to the MS4A tetraspan protein superfamily and is selectively expressed by the monocyte-macrophage lineage. In this study, we aimed to evaluate the role of MS4A4A+ macrophages in rheumatoid arthritis (RA) pathogenesis and response to treatment. RNA sequencing and immunohistochemistry of synovial samples from either early treatment-naïve or active chronic RA patients showed that MS4A4A expression positively correlated with synovial inflammation.
View Article and Find Full Text PDFAbnormal Amyloid-β Duration, Tau, and Neurodegeneration in Cranial Images.
JAMA Netw Open
September 2025
School of Medicine and Public Health, University of Wisconsin-Madison, Madison.
Importance: It is unclear whether the duration of amyloid-β (Aβ) pathology is associated with neurodegeneration and whether this depends on the presence of tau.
Objective: To examine the association of longitudinal atrophy with Aβ positron emission tomography (PET)-positivity (Aβ+) and the estimated duration of Aβ+ (Aβ+ duration), controlling for tau-positivity.
Design, Setting, And Participants: Data for this longitudinal cohort study were drawn from the Wisconsin Registry for Alzheimer Prevention and the Wisconsin Alzheimer Disease Research Center Clinical Core Study.
Gambling in the Shadow of War: Evidence of Increased Problem Gambling for Men with Difficulties in Emotional Regulation During a Mass Trauma.
J Gambl Stud
September 2025
Department of Psychology and Azrieli Israel Center for Addiction and Mental Health, The Hebrew University of Jerusalem, Jerusalem, Israel.
Research suggests that Problem Gambling (PG) may result from maladaptive emotional regulation strategies aimed at escaping emotions and stress caused by negative life events and trauma. The current study, aimed to examine the effect of exposure to the mass trauma of October 7, 2023 terror attack and the consequent Swords of Iron war in Israel, and difficulties in emotional regulation on PG. We utilized longitudinal data of self-reports in the Problem Gambling Severity Index collected before the terror attack (April 2022) and during the Swords of Iron war (December 2023, March 2024, June 2024; N = 899) from a large sample of adult Jewish Israelis.
View Article and Find Full Text PDFThe Development of Stakeholder-Driven and Theory-Informed Depression Care Decision Aid for Ethnoracially Diverse Communities in Primary Care.
Community Ment Health J
September 2025
Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, 10027, USA.
Guided by the Ottawa Decision Support Framework, we created a depression care decision aid for Latinx and African American individuals with major depressive disorder (MDD) at a network of Federally Qualified Health Centers. We surveyed 94 African American and Latinx individuals with MDD about their decision making needs. Focus groups elaborated on these preferences.
View Article and Find Full Text PDF